Research progress on different drug treatments for patent ductus arteriosus in preterm

VernacularTitle:早产儿动脉导管未闭不同药物治疗方案的研究进展
Author: Leyao WANG ¹ ; Siyuan XU ; Xiangyu GAO
Author Information

1. 徐州市中心医院(徐州医科大学徐州临床学院)新生儿科，徐州　221009
Keywords: Patent ductus arteriosus; Drug treatment; Infant, premature
From: Chinese Journal of Applied Clinical Pediatrics 2024;39(8):633-636
CountryChina
Language:Chinese
Abstract: The optimal drug treatment for preterm infants with hemodynamically significant patent ductus arteriosus (hsPDA) is still controversial.The prophylactic intravenous injection of indomethacin can be considered for extremely preterm infants or extremely low birth weight infants with a high risk of severe intraventricular hemorrhage.The expectant management without drug intervention can be chosen in the following situations: asymptomatic; preterm infants with gestational age ≥28 weeks or birth weight ≥1 000 g are born within 7-14 days; and there are few risk factors affecting spontaneous closure of hsPDA.The drug intervention can be given if the expectant management fails.Oral administration of high-dose Ibuprofen, Acetaminophen and standard-dose Ibuprofen are recommended.